---
title: "Onvuzosiran (ADX-324) in Prophylaxis of hereditary angioedema attacks: Humanistic burden and health-related quality of life"
description: "Formulary evidence on Onvuzosiran (ADX-324) in Prophylaxis of hereditary angioedema attacks: Humanistic burden and health-related quality of life. Topics: Burden of disease in adults: multinational survey; Multinational adult survey: treatment exposure and quality-of-life outcomes; Patient preferences for long-term prophylaxis: discrete-choice experiment; Health-related quality of life, depression, and work productivity: US patient survey; 4 further topics. 8 evidence topics quoted from 7 sources."
canonical: "https://www.evicenter.com/drugs/onvuzosiran--prophylaxis-of-hereditary-angioedema-attacks/product-information-and-disease-description/humanistic-burden-and-health-related-quality-of-life"
published: "2026-11-15T22:20:57-05:00"
modified: "2026-11-17T19:46:25-05:00"
---

# Onvuzosiran (ADX-324) in Prophylaxis of hereditary angioedema attacks: Humanistic burden and health-related quality of life

<a id="heading-2.2.1.8.1"></a>

## 2.2.1.8.1 Humanistic Burden and Health-related Quality of Life

<a id="topic-2.2.1.8.1-1"></a>

### Burden of disease in adults: multinational survey

> “In the survey, participants reported 11.5 ± 14.2 HAE attacks (mean ± SD) in the past 6 months.”

Source: [Watt et al. (2026)](https://link.springer.com/article/10.1186/s13023-025-04134-z)

<a id="topic-2.2.1.8.1-2"></a>

### Multinational adult survey: treatment exposure and quality-of-life outcomes

| Measure | Reported result |
| --- | --- |
| Participants included | “260” |
| Participants using any long-term prophylaxis | “153 (58.8%)” |
| First-line prophylaxis among prophylaxis users, per study classification | “56/153 (36.6%)” |
| AE-QoL total score, mean ± SD | “42.9 ± 23.2” |
| Participants with AE-QoL total score ≥39 | “137 of 260 (52.7%)” |
| Moderate to severe anxiety by HADS | “69 (26.5%)” |
| Moderate to severe depression by HADS | “27 (10.4%)” |

Source: [Watt et al. (2026)](https://link.springer.com/article/10.1186/s13023-025-04134-z)

<a id="topic-2.2.1.8.1-3"></a>

### Patient preferences for long-term prophylaxis: discrete-choice experiment

> “A reduction in attack frequency is the most important treatment feature for adults living with hereditary angioedema.”

Source: [Villa et al. (2026)](https://link.springer.com/article/10.1007/s40271-025-00798-8)

<a id="topic-2.2.1.8.1-4"></a>

### Health-related quality of life, depression, and work productivity: US patient survey

> “A total of 457 HAE patients responded to the survey (response rate, ∼19%).”
> “Patients reported significantly poorer health-related quality of life versus population norms, based on the SF-12 Physical Component Summary (mean, 43.7 versus 49.6; p < 0.001) and Mental Component Summary (mean, 42.6 versus 49.4; p < 0.001).”
> “HAE patients also had higher mean HDI-SF scores than population norms (8.1 ± 6.5 versus 3.1 ± 3.0; p < 0.001), with 42.5% of HAE patients scoring >8.5, indicative of depressive symptomatology.”
> “Productivity was also markedly impaired in all WPAI-GH categories, including 34% overall work impairment.”
> “Because of their most recent HAE attack, workers lost a mean of 3.3 days; students lost a mean of 1.9 days.”

Source: [Lumry et al. (2010)](https://pubmed.ncbi.nlm.nih.gov/20929608/)

<a id="topic-2.2.1.8.1-5"></a>

### Anxiety and depression: health technology assessment background

> “Studies have shown that almost three-quarters of HAE patients noted that the disease had a significant impact on their quality of life, including anxiety (15% of patients) and depression (almost 40% of patients) related to their ability to carry out daily activities, fear of attacks, and concerns about transmission of the condition to their children.”

Source: [ICER final evidence report (2018)](https://icer.org/wp-content/uploads/2020/10/ICER_HAE_Final_Evidence_Report_111518-1.pdf)

<a id="topic-2.2.1.8.1-6"></a>

### Quality of life with subcutaneous prophylaxis compared with on-demand treatment alone: US patient survey

> “The greatest improvement in QoL was seen in patients who used novel SC prophylactic therapies, with a 59.5% (p < 0.01) improvement in median impairment scores versus on-demand–only treatment.”
> “In addition, patients who used novel SC prophylactic therapies reported a 77% reduction in the number of attacks each year when compared with those who used on-demand–only treatment.”

Source: [Castaldo et al. (2021)](https://pmc.ncbi.nlm.nih.gov/articles/PMC8133018/)

<a id="topic-2.2.1.8.1-7"></a>

### Burden despite current therapies: US adult survey

> “A web-based survey was conducted from March to April 2025 among 100 US adults with HAE-C1INH currently receiving long-term prophylaxis and/or on-demand therapies.”
> “Even with treatment, 80% of respondents reported ≥1 HAE attack in the past year and 61% thought about HAE at least weekly.”
> “Mental health was the aspect that respondents felt was most impacted by HAE (54% of respondents), and 73% reported taking ≥2 measures to avoid attack triggers.”
> “Several concerns impacted the ability to reach normalization; lifetime use of medication was the most commonly reported concern (68% of respondents).”
> “The greatest unmet needs associated with long-term prophylaxis were cost- and access-related.”

Source: [Busse et al. (2026)](https://pubmed.ncbi.nlm.nih.gov/41698689/)

<a id="topic-2.2.1.8.1-8"></a>

### Preferences for long-term prophylaxis and willingness to switch: US adult survey

> “A total of 150 individuals completed the survey.”
> “Respondents rated effectiveness in preventing attacks and reducing the severity of attacks as the most important LTP attributes.”
> “Route of administration and convenience were more than twice as important as dosing frequency.”
> “Individuals preferred oral daily therapy to biweekly (54% vs 46%) or monthly injections (54% vs 46%).”
> “Most individuals (71%) were at least somewhat willing to switch LTP treatments in the next 6 months, particularly those whose HAE was not well controlled, were anxious about taking LTP, were burdened by treating their HAE, or preferred oral administration.”

Source: [Olson et al. (2026)](https://pubmed.ncbi.nlm.nih.gov/41429313/)

## Related pages
- [Onvuzosiran (ADX-324): Prophylaxis of hereditary angioedema attacks](https://www.evicenter.com/drugs/onvuzosiran--prophylaxis-of-hereditary-angioedema-attacks) · [Markdown](https://www.evicenter.com/drugs/onvuzosiran--prophylaxis-of-hereditary-angioedema-attacks.md)
- [Onvuzosiran (ADX-324) in Prophylaxis of hereditary angioedema attacks: Terms and abbreviations](https://www.evicenter.com/drugs/onvuzosiran--prophylaxis-of-hereditary-angioedema-attacks/terms-and-abbreviations) · [Markdown](https://www.evicenter.com/drugs/onvuzosiran--prophylaxis-of-hereditary-angioedema-attacks/terms-and-abbreviations.md)
- [Onvuzosiran (ADX-324): Prophylaxis of hereditary angioedema attacks](https://www.evicenter.com/drugs/onvuzosiran--prophylaxis-of-hereditary-angioedema-attacks/executive-summary) · [Markdown](https://www.evicenter.com/drugs/onvuzosiran--prophylaxis-of-hereditary-angioedema-attacks/executive-summary.md)
- [Onvuzosiran (ADX-324) in Prophylaxis of hereditary angioedema attacks: Product information and disease description](https://www.evicenter.com/drugs/onvuzosiran--prophylaxis-of-hereditary-angioedema-attacks/product-information-and-disease-description) · [Markdown](https://www.evicenter.com/drugs/onvuzosiran--prophylaxis-of-hereditary-angioedema-attacks/product-information-and-disease-description.md)
- [Onvuzosiran (ADX-324) in Prophylaxis of hereditary angioedema attacks: Clinical evidence](https://www.evicenter.com/drugs/onvuzosiran--prophylaxis-of-hereditary-angioedema-attacks/clinical-evidence) · [Markdown](https://www.evicenter.com/drugs/onvuzosiran--prophylaxis-of-hereditary-angioedema-attacks/clinical-evidence.md)
- [Onvuzosiran (ADX-324) in Prophylaxis of hereditary angioedema attacks: Economic information and modeling report](https://www.evicenter.com/drugs/onvuzosiran--prophylaxis-of-hereditary-angioedema-attacks/economics) · [Markdown](https://www.evicenter.com/drugs/onvuzosiran--prophylaxis-of-hereditary-angioedema-attacks/economics.md)
- [Onvuzosiran (ADX-324) in Prophylaxis of hereditary angioedema attacks: References](https://www.evicenter.com/drugs/onvuzosiran--prophylaxis-of-hereditary-angioedema-attacks/references) · [Markdown](https://www.evicenter.com/drugs/onvuzosiran--prophylaxis-of-hereditary-angioedema-attacks/references.md)
